UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis

Alimentary pharmacology & therapeutics, 2021-03, Vol.53 (6), p.733-744

2021

Volltextzugriff (PDF)

Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection

Hepatology (Baltimore, Md.), 2012-06, Vol.55 (6), p.1700-1710

2012

Volltextzugriff (PDF)

The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment

Cancers, 2022-10, Vol.14 (21), p.5323

2022

Volltextzugriff (PDF)

Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular Carcinomas

Cancers, 2022-09, Vol.14 (19), p.4807

2022

Volltextzugriff (PDF)

Clinical applications of circulating HBV RNA as a potential surrogate biomarker for intrahepatic cccDNA transcriptional activity

Gut, 2023-12, Vol.73 (4), p.563-566

2023

Volltextzugriff (PDF)

Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B

Liver international, 2018-02, Vol.38 (S1), p.90-96

2018

Volltextzugriff (PDF)

Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B

Journal of hepatology, 2021-02, Vol.74 (2), p.283-292

2021

Volltextzugriff (PDF)

Three are better than one—increasing HBV seroprotection by a tri-antigenic vaccine

The Lancet infectious diseases, 2021-09, Vol.21 (9), p.1197-1198

2021

Volltextzugriff (PDF)

Surrogate Markers for Hepatitis B Virus Covalently Closed Circular DNA

Seminars in liver disease, 2022-08, Vol.42 (3), p.327-340

2022

Volltextzugriff (PDF)

Prävention der nosokomialen Übertragung von Hepatitis-B-Virus (HBV) und Hepatitis-C-Virus (HCV) durch im Gesundheitswesen Tätige: Empfehlungen der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e. V

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2020-02, Vol.63 (2), p.218-225

2020

Volltextzugriff (PDF)

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers

Gut, 2018-11, Vol.67 (11), p.2045-2053

2018

Volltextzugriff (PDF)

Commentary: Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance

Frontiers in immunology, 2022-12, Vol.13, p.1081730-1081730

2022

Volltextzugriff (PDF)

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment

Hepatology (Baltimore, Md.), 2018-09, Vol.68 (3), p.839-847

2018

Volltextzugriff (PDF)

Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B

Hepatology communications, 2021-10, Vol.5 (10), p.1632-1648

2021

Volltextzugriff (PDF)

Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians

Hepatology research, 2023-12, Vol.53 (12), p.1156-1168

2023

Volltextzugriff (PDF)

Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)

The Lancet infectious diseases, 2016-05, Vol.16 (5), p.606-617

2016

Volltextzugriff (PDF)

Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population

Scientific reports, 2018-08, Vol.8 (1), p.12737-8, Article 12737

2018

Volltextzugriff (PDF)

Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery

PloS one, 2021-07, Vol.16 (7), p.e0254817-e0254817

2021

Volltextzugriff (PDF)

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

Nature reviews. Gastroenterology & hepatology, 2022-11, Vol.19 (11), p.727-745

2022

Volltextzugriff (PDF)

Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss

Alimentary pharmacology & therapeutics, 2021-01, Vol.53 (2), p.314-320

2021

Volltextzugriff (PDF)

Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B

Journal of viral hepatitis, 2020-06, Vol.27 (6), p.610-619

2020

Volltextzugriff (PDF)

Association of HLA‐DPA1 and HLA‐DPB1 polymorphisms with spontaneous HBsAg seroclearance in Caucasians

Liver international, 2019-04, Vol.39 (4), p.646-654

2019

Volltextzugriff (PDF)

Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan

Cancers, 2023-07, Vol.15 (15), p.3776

2023

Volltextzugriff (PDF)

Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers

Cardiovascular and interventional radiology, 2022-02, Vol.45 (2), p.218-222

2022

Volltextzugriff (PDF)

1 – 25 von 180

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(173)
Mit Volltextzugriff
(169)

Publikationsform

Sprache

Englisch
(167)
Deutsch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(84)
Life Sciences & Biomedicine
(80)
Humans
(56)
Gastroenterology & Hepatology
(54)
Hepatitis B
(36)
Male
(26)
Antiviral Agents - Therapeutic Use
(25)
Middle Aged
(25)
Adult
(23)
Female
(23)
Hepatitis B Virus - Genetics
(22)
Hepatitis B, Chronic - Drug Therapy
(21)
Hepatitis
(20)
Treatment Outcome
(20)
Patients
(17)
Hepatitis B Virus
(15)
Tenofovir
(15)
Hepatitis B Surface Antigen
(14)
Liver Cancer
(13)
Liver Cirrhosis
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Hepatology
(72)
Hepatology
(15)
Liver International
(8)
Gastroenterology
(6)
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
(5)
Cancers
(4)
Gut
(4)
Jhep Reports
(4)
Die Anaesthesiologie
(3)
Gastro-News
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis

Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection

Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience

The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment

Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular Carcinomas

Clinical applications of circulating HBV RNA as a potential surrogate biomarker for intrahepatic cccDNA transcriptional activity

Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B

Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B

Three are better than one—increasing HBV seroprotection by a tri-antigenic vaccine

Surrogate Markers for Hepatitis B Virus Covalently Closed Circular DNA

Prävention der nosokomialen Übertragung von Hepatitis-B-Virus (HBV) und Hepatitis-C-Virus (HCV) durch im Gesundheitswesen Tätige: Empfehlungen der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e. V

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers

Commentary: Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment

Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B

Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians

Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)

Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population

Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss

Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B

Association of HLA‐DPA1 and HLA‐DPB1 polymorphisms with spontaneous HBsAg seroclearance in Caucasians

Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan

Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers

Suchergebnisse filtern